⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16568751 | 1.00 | — | — | |
| SCHEMBL17055830 | 1.00 | — | — | |
| Bicarbonate SCHEMBL6986469 | 0.89 | FFAR3 (0.36) | — | |
| SCHEMBL27827278 | 0.79 | — | — | |
| SCHEMBL7733958 | 0.77 | — | — | |
| SCHEMBL9715813 | 0.77 | — | — | |
| SCHEMBL21466607 | 0.77 | — | — | |
| SCHEMBL10062273 | 0.77 | — | — | |
| SCHEMBL1017090 | 0.77 | — | — | |
| SCHEMBL31328381 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119026-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2024-06-06 | — | — | WO | disclosed |
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| EP-4242285-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4230618-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023278564-A1 | AMINOPYRIDINE-BASED MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022109078-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109209-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | TELO THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021070054-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-15 | — | — | WO | disclosed |
| EP-3763706-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2020114477-A1 | COMPOUND ACTING AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海济煜医药科技有限公司 | 2020-06-11 | — | — | WO | disclosed |
| EP-3453702-A2 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | Merial, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-10011568-B2 | Cyclohexyl pyridine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170298024-A1 | CYCLOHEXYL PYRIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-01-12 | — | — | US | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |